An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer (pages 976–982)
Walter M. Stadler, David J. Vaughn, Guru Sonpavde, Nicholas J. Vogelzang, Scott T. Tagawa, Daniel P. Petrylak, Peter Rosen, Chia-Chi Lin, John Mahoney, Sanjiv Modi, Peter Lee, Marc S. Ernstoff, Wu-Chou Su, Alexander Spira, Korinna Pilz, Richard Vinisko, Charles Schloss, Holger Fritsch, Charles Zhao and Michael A. Carducci
Article first published online: 11 DEC 2013 | DOI: 10.1002/cncr.28519
In this open-label, single-arm, phase 2 trial of volasertib as a second-line treatment in patients with advanced or metastatic urothelial cancer, responses are achieved with a manageable safety profile. However, there is insufficient activity for further clinical investigation of volasertib as a single agent in this setting.